GlassScriptPhysician profile
Kaveh Alizadeh
NPI 1770552465
$27,020.16
in general payments reported to CMS, 2019-2025
12 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $241 · 2021: $530 · 2022: $415 · 2023: $845 · 2024: $943 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457 · Consulting Fee: $500 · Gift: $24.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.76 |
| Consulting Fee | $500.00 |
| Gift | $24.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21,708.03 | 2019-2022 | |
| Merz North America, INC. | $2,496.38 | 2019-2024 | Xeomin |
| Sientra, INC. | $883.27 | 2019-2022 | |
| Becton, Dickinson and Company | $500.00 | 2024 | |
| Integra Lifesciences Corporation | $399.70 | 2022-2025 | Integra, Durasorb Monofilament Mesh, Primatrix |
| Abbvie INC. | $246.06 | 2021-2023 | Botox |
| Stryker Corporation | $174.94 | 2023 | Na, Vsp System, Vsp Cranial, Delta |
| Smith+Nephew, INC. | $168.32 | 2021-2023 | Grafix Pl |
| Galderma Laboratories, L.P. | $149.64 | 2020-2021 | |
| Axogen | $141.97 | 2024 | Axoguard Nerve Cap, Axoguard Nerve Connector, Avance Nerve Graft |
| Revance Therapeutics, INC. | $113.74 | 2024 | Daxxify |
| Hikma Pharmaceuticals USA | $38.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaveh Alizadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.